{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:43:01Z","timestamp":1790541781966,"version":"4.1.0"},"reference-count":207,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.pharmthera.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T07:31:43Z","timestamp":1495524703000},"page":"111-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge"],"prefix":"10.1016","volume":"179","author":[{"given":"Vincent","family":"Goffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2017.05.009_bb0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1634\/theoncologist.2015-0502","article-title":"Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate cancer","volume":"21","author":"Agarwal","year":"2016","journal-title":"The Oncologist"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0010","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1210\/endo.140.11.7090","article-title":"Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture","volume":"140","author":"Ahonen","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1210\/endo.143.1.8576","article-title":"PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro","volume":"143","author":"Ahonen","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0020","doi-asserted-by":"crossref","first-page":"27287","DOI":"10.1074\/jbc.M304307200","article-title":"Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells","volume":"278","author":"Ahonen","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0025","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.cellsig.2011.06.014","article-title":"Prolactin-stimulated activation of ERK1\/2 mitogen-activated protein kinases is controlled by PI3-kinase\/Rac\/PAK signaling pathway in breast cancer cells","volume":"23","author":"Aksamitiene","year":"2011","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.14694\/EDBK_159135","article-title":"The evolution of triple-negative breast cancer: From biology to novel therapeutics","volume":"35","author":"Anders","year":"2016","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0035","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0040","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2353\/ajpath.2006.050861","article-title":"Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice","volume":"168","author":"Arendt","year":"2006","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0045","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/bcr2819","article-title":"Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer","volume":"13","author":"Arendt","year":"2011","journal-title":"Breast Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10911-008-9073-9","article-title":"Transgenic models to study actions of prolactin in mammary neoplasia","volume":"13","author":"Arendt","year":"2008","journal-title":"Journal of Mammary Gland Biology and Neoplasia"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116891","article-title":"Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells","volume":"10","author":"Barcus","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0060","doi-asserted-by":"crossref","first-page":"12722","DOI":"10.1074\/jbc.M112.447631","article-title":"Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells","volume":"288","author":"Barcus","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0065","doi-asserted-by":"crossref","first-page":"48093","DOI":"10.18632\/oncotarget.10137","article-title":"Prolactin signaling through focal adhesion complexes is amplified by stiff extracellular matrices in breast cancer cells","volume":"7","author":"Barcus","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13058-017-0801-1","article-title":"Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells","volume":"19","author":"Barcus","year":"2017","journal-title":"Breast Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0075","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1073\/pnas.87.18.6934","article-title":"Structural design of molecular evolution of a cytokine receptor superfamily","volume":"87","author":"Bazan","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0080","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-11-0076","article-title":"Cancer risk in hyperprolactinemia patients: A population-based cohort study","volume":"165","author":"Berinder","year":"2011","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0090","doi-asserted-by":"crossref","first-page":"35988","DOI":"10.1074\/jbc.M305687200","article-title":"Development of pure prolactin receptor antagonists","volume":"278","author":"Bernichtein","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0095","doi-asserted-by":"crossref","first-page":"14533","DOI":"10.1073\/pnas.0800685105","article-title":"Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors","volume":"105","author":"Bogorad","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1210\/edrv.19.3.0334","article-title":"Prolactin and its receptor: Actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice","volume":"19","author":"Bole-Feysot","year":"1998","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0105","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0277-5379(86)90141-0","article-title":"Correlation between prolactin receptors (PRL R), estradiol (ER) and progesterone receptors (PgR) in human breast cancer","volume":"22","author":"Bonneterre","year":"1986","journal-title":"European Journal of Cancer & Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0110","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I","article-title":"Prostatic intra-epithelial neoplasia and early invasion in prostate cancer","volume":"59","author":"Bostwick","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00428-005-0056-6","article-title":"STAT 5a expression in various lesions of the breast","volume":"448","author":"Bratthauer","year":"2006","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0120","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","article-title":"JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: A rationale for cotargeting these pathways in metastatic breast cancer","volume":"22","author":"Britschgi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0125","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/mend.16.4.0817","article-title":"PRL activates the cyclin D1 promoter via the Jak2\/Stat pathway","volume":"16","author":"Brockman","year":"2002","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1210\/er.2011-1040","article-title":"Molecular mechanisms of prolactin and its receptor","volume":"33","author":"Brooks","year":"2012","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0135","doi-asserted-by":"crossref","first-page":"1249783","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","author":"Brooks","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0140","doi-asserted-by":"crossref","first-page":"8422","DOI":"10.1074\/jbc.M109.089128","article-title":"Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2","volume":"285","author":"Broutin","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0145","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nsmb977","article-title":"Model for growth hormone receptor activation based on subunit rotation within a receptor dimer","volume":"12","author":"Brown","year":"2005","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0150","doi-asserted-by":"crossref","first-page":"11578","DOI":"10.1038\/ncomms11578","article-title":"A combined computational and structural model of the full-length human prolactin receptor","volume":"7","author":"Bugge","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0155","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0165","first-page":"431","article-title":"Expression of human, nut not bovine, growth hormone promotes development of mammary tumors in transgenic mice","volume":"1","author":"Cecim","year":"1994","journal-title":"Transgenics"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0170","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1210\/jc.2016-2372","article-title":"Gain-of-function prolactin receptor variants are not associated with breast cancer and multiple fibroadenoma risk","volume":"101","author":"Chakhtoura","year":"2016","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-319-12114-7_3","article-title":"The many faces of prolactin in breast cancer","volume":"846","author":"Chen","year":"2015","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0180","first-page":"813","article-title":"In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R","volume":"20","author":"Chen","year":"2002","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0185","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1101\/gad.197343.112","article-title":"Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways","volume":"26","author":"Chen","year":"2012","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2001-0036","article-title":"The role of prolactin in mammary carcinoma","volume":"24","author":"Clevenger","year":"2003","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0195","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.tem.2009.03.001","article-title":"New mechanisms for PRLr action in breast cancer","volume":"20","author":"Clevenger","year":"2009","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0200","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10911-008-9074-8","article-title":"From bench to bedside: Future potential for the translation of prolactin inhibitors as breast cancer therapeutics","volume":"13","author":"Clevenger","year":"2008","journal-title":"Journal of Mammary Gland Biology and Neoplasia"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/jc.2009-1494","article-title":"Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas","volume":"95","author":"Courtillot","year":"2010","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jsbmb.2004.10.017","article-title":"Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development","volume":"92","author":"Cunha","year":"2004","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0215","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0220","first-page":"186","article-title":"Prolactin promotes breast cancer cell migration through actin cytoskeleton remodeling","volume":"6","author":"da Silva","year":"2015","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0225","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.str.2011.12.010","article-title":"The WSXWS motif in cytokine receptors is a molecular switch involved in receptor activation: Insight from structures of the prolactin receptor","volume":"20","author":"Dagil","year":"2012","journal-title":"Structure"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0230","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1210\/en.2006-1761","article-title":"Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a\/b signaling pathway","volume":"148","author":"Dagvadorj","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0235","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-07-2024","article-title":"Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo","volume":"14","author":"Dagvadorj","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0240","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/1535-7163.MCT-12-0886","article-title":"Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer","volume":"12","author":"Damiano","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0245","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1078-0432.CCR-12-0138","article-title":"Molecular pathways: Blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer","volume":"19","author":"Damiano","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0250","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.yexcr.2016.12.020","article-title":"STAT5A-mediated NOX5-L expression promotes the proliferation and metastasis of breast cancer cells","volume":"351","author":"Dho","year":"2017","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0255","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pros.2990110304","article-title":"Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement","volume":"11","author":"English","year":"1987","journal-title":"Prostate"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0260","first-page":"104","article-title":"The role of Stat5 transcription factors as tumor suppressors or oncogenes","volume":"1815","author":"Ferbeyre","year":"2011","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0265","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2826.2010.02011.x","article-title":"Prolactin and human tumorogenesis","volume":"22","author":"Fernandez","year":"2010","journal-title":"Journal of Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0270","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000354701","article-title":"Use of prolactin receptor antagonist to better understand prolactin regulation of pituitary homeostasis","volume":"98","author":"Ferraris","year":"2013","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0275","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1042\/bst0290038","article-title":"Ontogenesis of prolactin receptors in the human fetus: Roles in fetal development","volume":"29","author":"Freemark","year":"2001","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0280","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1210\/me.2006-0114","article-title":"Ligand-independent dimerization of the human prolactin receptor isoforms: Functional implications","volume":"20","author":"Gadd","year":"2006","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0285","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1677\/JOE-08-0479","article-title":"Re-evaluation of the prolactin receptor expression in human breast cancer","volume":"201","author":"Galsgaard","year":"2009","journal-title":"The Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0290","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0295","first-page":"2591","article-title":"Prolactin synthesis and secretion by human breast cancer cells","volume":"55","author":"Ginsburg","year":"1995","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0300","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/er.2004-0016","article-title":"Development and potential clinical uses of human prolactin receptor antagonists","volume":"26","author":"Goffin","year":"2005","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1050-3862(99)00025-X","article-title":"From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models","volume":"15","author":"Goffin","year":"1999","journal-title":"Genetic Analysis"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0310","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrurol.2011.143","article-title":"Prolactin regulation of the prostate gland: A female player in a male game","volume":"8","author":"Goffin","year":"2011","journal-title":"Nature Reviews. Urology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0315","doi-asserted-by":"crossref","first-page":"16573","DOI":"10.1074\/jbc.271.28.16573","article-title":"Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay","volume":"271","author":"Goffin","year":"1996","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0320","first-page":"385","article-title":"Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals","volume":"17","author":"Goffin","year":"1996","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0325","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/14728222.2015.1053209","article-title":"The prolactin receptor as a therapeutic target in human diseases: Browsing new potential indications","volume":"19","author":"Goffin","year":"2015","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0330","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1126\/science.1189992","article-title":"Identification of a cell of origin for human prostate cancer","volume":"329","author":"Goldstein","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0335","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molonc.2010.06.009","article-title":"Primitive origins of prostate cancer: In vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells","volume":"4","author":"Goldstein","year":"2010","journal-title":"Molecular Oncology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0340","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1101\/gad.222380.113","article-title":"Does the microenvironment influence the cell types of origin for prostate cancer?","volume":"27","author":"Goldstein","year":"2013","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0345","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1002\/j.1460-2075.1994.tb06756.x","article-title":"Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription","volume":"13","author":"Gouilleux","year":"1994","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0350","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.celrep.2016.08.076","article-title":"Truncating prolactin receptor mutations promote tumor growth in murine estrogen receptor-alpha mammary carcinomas","volume":"17","author":"Griffith","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0355","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2353\/ajpath.2010.090653","article-title":"Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth","volume":"176","author":"Gu","year":"2010","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0360","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/1078-0432.CCR-13-0422","article-title":"Pharmacologic inhibition of Jak2-Stat5 signaling by Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer","volume":"19","author":"Gu","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0365","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-13-0605","article-title":"Pharmacologic suppression of JAK1\/2 by JAK1\/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation","volume":"13","author":"Gu","year":"2014","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0370","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1677\/ERC-09-0328","article-title":"Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo","volume":"17","author":"Gu","year":"2010","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0375","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/PAI.0000000000000178","article-title":"Prolactin receptor expression is an independent favorable prognostic marker in human breast cancer","volume":"24","author":"Hachim","year":"2016","journal-title":"Applied Immunohistochemistry & Molecular Morphology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0380","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.humpath.2016.02.010","article-title":"A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome","volume":"53","author":"Hachim","year":"2016","journal-title":"Human Pathology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0385","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.ajpath.2013.02.044","article-title":"STAT5A\/B gene locus undergoes amplification during human prostate cancer progression","volume":"182","author":"Haddad","year":"2013","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0390","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-319-12114-7_5","article-title":"Tyrosyl phosphorylated serine-threonine kinase PAK1 is a novel regulator of prolactin-dependent breast cancer cell motility and invasion","volume":"846","author":"Hammer","year":"2015","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0395","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12860-016-0109-5","article-title":"Prolactin-induced PAK1 tyrosyl phosphorylation promotes FAK dephosphorylation, breast cancer cell motility, invasion and metastasis","volume":"17","author":"Hammer","year":"2016","journal-title":"BMC Cell Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0400","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jnci\/91.7.629","article-title":"Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women","volume":"91","author":"Hankinson","year":"1999","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0405","doi-asserted-by":"crossref","first-page":"21388","DOI":"10.1074\/jbc.M116.726190","article-title":"Identification of NEK3 kinase threonine 165 as a novel regulatory phosphorylation site that modulates focal adhesion remodeling necessary for breast cancer cell migration","volume":"291","author":"Harrington","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0410","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrm1714","article-title":"Information networks in the mammary gland","volume":"6","author":"Hennighausen","year":"2005","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0415","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/1535-7163.MCT-14-0819","article-title":"Inhibition of Stat5a\/b enhances proteasomal degradation of androgen receptor liganded by antiandrogens in prostate cancer","volume":"14","author":"Hoang","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0420","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1210\/edrv-15-5-627","article-title":"Transcriptional regulation by the helix bundle peptide hormones: Growth hormone, prolactin, and hematopoietic cytokines","volume":"15","author":"Horseman","year":"1994","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0425","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1093\/emboj\/16.23.6926","article-title":"Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene","volume":"16","author":"Horseman","year":"1997","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0430","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr2129","article-title":"Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity","volume":"10","author":"Howell","year":"2008","journal-title":"Breast Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0435","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1586\/eem.11.19","article-title":"Lactogens and estrogens in breast cancer chemoresistance","volume":"6","author":"Idelman","year":"2011","journal-title":"Expert Review of Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0440","first-page":"315","article-title":"Prolactin in breast and prostate cancer: Molecular and genetic perspectives","volume":"11","author":"Jacobson","year":"2011","journal-title":"Discovery Medicine"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0445","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tem.2010.08.004","article-title":"Unexploited therapies in breast and prostate cancer: Blockade of the prolactin receptor","volume":"21","author":"Jacobson","year":"2010","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0450","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0455","doi-asserted-by":"crossref","first-page":"33118","DOI":"10.1074\/jbc.M704364200","article-title":"Structural and thermodynamical bases for the design of pure prolactin receptor antagonists. X-ray structure of Del1-9-G129R-hPRL","volume":"282","author":"Jomain","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0460","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.1146812","article-title":"Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus","volume":"318","author":"Karnik","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0465","doi-asserted-by":"crossref","first-page":"27353","DOI":"10.18632\/oncotarget.16040","article-title":"Role of EGF\/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells","volume":"8","author":"Kavarthapu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0470","first-page":"8757","article-title":"Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: Evidence from the transgenic adenocarcinoma of the mouse prostate system","volume":"63","author":"Kazansky","year":"2003","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0475","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.1158\/0008-5472.CAN-04-3937","article-title":"Medullary thyroid carcinoma arises in the absence of prolactin signaling","volume":"65","author":"Kedzia","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0480","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1006\/frne.2001.0212","article-title":"Implications of multiple phenotypes observed in prolactin receptor knockout mice","volume":"22","author":"Kelly","year":"2001","journal-title":"Frontiers in Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0485","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/pros.10113","article-title":"Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels","volume":"53","author":"Kindblom","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0490","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1210\/en.2002-0187","article-title":"Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin","volume":"144","author":"Kindblom","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0495","doi-asserted-by":"crossref","first-page":"E592","DOI":"10.1073\/pnas.1318157111","article-title":"Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin","volume":"111","author":"Kwon","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0500","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/stem.2217","article-title":"Stem cell antigen-1 identifies a distinct androgen-independent murine prostatic luminal cell lineage with bipotent potential","volume":"34","author":"Kwon","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0505","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1677\/ERC-09-0253","article-title":"Novel roles of prolactin and estrogens in breast cancer: Resistance to chemotherapy","volume":"17","author":"Lapensee","year":"2010","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0510","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mce.2011.09.020","article-title":"Interplay between progesterone and prolactin in mammary development and implications for breast cancer","volume":"357","author":"Lee","year":"2012","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0515","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0520","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-03-3499","article-title":"Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade","volume":"64","author":"Li","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0525","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1158\/1078-0432.CCR-05-0562","article-title":"Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence","volume":"11","author":"Li","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0530","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1535-7163.MCT-14-0883","article-title":"Structure-based screen identifies a potent small molecule inhibitor of Stat5a\/b with therapeutic potential for prostate cancer and chronic myeloid leukemia","volume":"14","author":"Liao","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0535","first-page":"133","article-title":"Targeting transcription factor Stat5a\/b as a therapeutic strategy for prostate cancer","volume":"3","author":"Liao","year":"2011","journal-title":"American Journal of Translational Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0540","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1023956223037","article-title":"Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth","volume":"79","author":"Liby","year":"2003","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0545","article-title":"Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways","volume":"7","author":"Lim","year":"2012","journal-title":"PloS One"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2017.05.009_bb0550","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0959-8049(09)70012-7","article-title":"Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept","volume":"45","author":"Linn","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0555","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/protein\/gzr047","article-title":"Discovery of the improved antagonistic prolactin variants by library screening","volume":"24","author":"Liu","year":"2011","journal-title":"Protein Engineering, Design & Selection"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0560","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1101\/gad.11.2.179","article-title":"Stat5a is mandatory for adult mammary gland development and lactogenesis","volume":"11","author":"Liu","year":"1997","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0565","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1038\/sj.onc.1203846","article-title":"Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation","volume":"19","author":"Llovera","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0570","doi-asserted-by":"crossref","first-page":"30934","DOI":"10.1038\/srep30934","article-title":"Prolactin pro-differentiation pathway in triple negative breast cancer: Impact on prognosis and potential therapy","volume":"6","author":"Lopez-Ozuna","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0575","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1210\/endo.139.10.6243","article-title":"Null mutation of the prolactin receptor gene produces a defect in maternal behavior","volume":"139","author":"Lucas","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0580","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1210\/en.2005-0770","article-title":"Prolactin specifically activates STAT5b in neuroendocrine dopaminergic neurons","volume":"146","author":"Ma","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0585","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1210\/me.2013-1349","article-title":"Minireview: Extrapituitary prolactin: An update on the distribution, regulation, and functions","volume":"28","author":"Marano","year":"2014","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0590","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.14694\/EDBK_159167","article-title":"Emerging therapeutic options for HER2-positive breast cancer","volume":"35","author":"Martin","year":"2016","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0595","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-3-319-12114-7_7","article-title":"Role of SRC family kinases in prolactin signaling","volume":"846","author":"Martin-Perez","year":"2015","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0600","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1158\/0008-5472.CAN-04-1019","article-title":"Human prolactin receptor variants in breast cancer: Low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma","volume":"64","author":"Meng","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0605","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.humpath.2012.06.001","article-title":"Nuclear Stat5a\/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy","volume":"44","author":"Mirtti","year":"2013","journal-title":"Human Pathology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0610","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cyto.2016.01.013","article-title":"STAT5A is regulated by DNA damage via the tumor suppressor p53","volume":"82","author":"Mukhopadhyay","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0615","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/labinvest.3780105","article-title":"Epithelial defect in prostates of Stat5a-null mice","volume":"80","author":"Nevalainen","year":"2000","journal-title":"Laboratory Investigation"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0620","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1096\/fasebj.11.14.9409549","article-title":"Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture","volume":"11","author":"Nevalainen","year":"1997","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0625","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1172\/JCI119204","article-title":"Prolactin and prolactin receptors are expressed and functioning in human prostate","volume":"99","author":"Nevalainen","year":"1997","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0630","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.2004.11.046","article-title":"Signal transducer and activator of transcription-5 activation and breast cancer prognosis","volume":"22","author":"Nevalainen","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0635","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","article-title":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes","volume":"10","author":"Neve","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0640","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MED.0b013e32834c800d","article-title":"Placental hormones and the control of maternal metabolism and fetal growth","volume":"18","author":"Newbern","year":"2011","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0645","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12885-015-1445-0","article-title":"The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2\/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts","volume":"15","author":"Nipin","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0650","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10549-013-2731-7","article-title":"Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer","volume":"142","author":"Nitze","year":"2013","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0655","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/0008-5472.CAN-05-2292","article-title":"Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells","volume":"66","author":"Nouhi","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0660","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/bcr2864","article-title":"Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: Results from a population-based case-control study in Poland","volume":"13","author":"Nyante","year":"2011","journal-title":"Breast Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0665","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.onc.1209838","article-title":"Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions","volume":"26","author":"Oakes","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0670","first-page":"4483","article-title":"Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas","volume":"154","author":"O'Leary","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0675","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-3-319-12114-7_9","article-title":"Modeling prolactin actions in breast cancer in vivo: Insights from the NRL-PRL mouse","volume":"846","author":"O'Leary","year":"2015","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0680","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1101\/gad.11.2.167","article-title":"Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse","volume":"11","author":"Ormandy","year":"1997","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0685","first-page":"3692","article-title":"Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer","volume":"82","author":"Ormandy","year":"1997","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0690","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1210\/en.2015-1277","article-title":"A neutralizing prolactin receptor antibody whose in vivo application mimics the phenotype of female prolactin receptor-deficient mice","volume":"156","author":"Otto","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0695","first-page":"225","article-title":"Prolactin-dependent rat mammary cancer: A model for man?","volume":"82","author":"Pearson","year":"1969","journal-title":"Transactions of the Association of American Physicians"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0700","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/bcr3328","article-title":"Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes","volume":"14","author":"Peck","year":"2012","journal-title":"Breast Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0705","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1200\/JCO.2010.30.3552","article-title":"Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure","volume":"29","author":"Peck","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0710","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/me.2015-1299","article-title":"Prolactin signaling stimulates invasion via Na(+)\/H(+) exchanger NHE1 in T47D human breast cancer cells","volume":"30","author":"Pedraz-Cuesta","year":"2016","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0715","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1038\/sj.onc.1205484","article-title":"Loss of Stat5a delays mammary cancer progression in a mouse model","volume":"21","author":"Ren","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0720","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1210\/en.2003-0068","article-title":"Prostate development and carcinogenesis in prolactin receptor knockout mice","volume":"144","author":"Robertson","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0725","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063723","article-title":"Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer","volume":"8","author":"Roe","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0730","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/sj.onc.1206619","article-title":"Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice","volume":"22","author":"Rose-Hellekant","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0735","doi-asserted-by":"crossref","first-page":"15199","DOI":"10.1073\/pnas.0911651107","article-title":"Local prolactin is a target to prevent expansion of basal\/stem cells in prostate tumors","volume":"107","author":"Rouet","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0740","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.14694\/EDBK_159198","article-title":"Improving response to hormone therapy in breast cancer: New targets, new therapeutic options","volume":"35","author":"Rugo","year":"2016","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0745","doi-asserted-by":"crossref","first-page":"931s","DOI":"10.1158\/1078-0432.931s.11.2","article-title":"Breast differentiation and its implication in cancer prevention","volume":"11","author":"Russo","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0750","first-page":"1","article-title":"Amplified luminal progenitors in prostates of prolactin-transgenic mice","author":"Sackmann Sala","year":"2014","journal-title":"Cancer Cell and Microenvironment"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0755","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygcen.2015.04.007","article-title":"Human and murine prostate basal\/stem cells are not direct targets of prolactin","volume":"220","author":"Sackmann-Sala","year":"2015","journal-title":"General and Comparative Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0760","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1016\/j.ajpath.2014.07.020","article-title":"Prolactin-induced prostate tumorigenesis links sustained Stat5 signaling with the amplification of basal\/stem cells and emergence of putative luminal progenitors","volume":"184","author":"Sackmann-Sala","year":"2014","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0765","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-3-319-12114-7_10","article-title":"Prolactin-induced prostate tumorigenesis","volume":"846","author":"Sackmann-Sala","year":"2015","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0770","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/me.2015-1022","article-title":"Minireview: Prolactin regulation of adult stem cells","volume":"29","author":"Sackmann-Sala","year":"2015","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb9900","doi-asserted-by":"crossref","DOI":"10.1002\/path.4924","article-title":"A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumors","author":"Sackmann Sala","year":"2017","journal-title":"Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0775","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1038\/onc.2010.274","article-title":"Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer","volume":"29","author":"Sakamoto","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0780","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/modpathol.2009.103","article-title":"Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate","volume":"22","author":"Sanati","year":"2009","journal-title":"Modern Pathology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0785","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1038\/onc.2013.172","article-title":"Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression","volume":"33","author":"Sato","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0790","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1172\/JCI0215912","article-title":"Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms","volume":"110","author":"Schuff","year":"2002","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0795","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-007-9789-z","article-title":"Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells","volume":"111","author":"Scotti","year":"2008","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0800","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/JME-16-0150","article-title":"Prolactin receptor in breast cancer: Marker for metastatic risk","volume":"57","author":"Shemanko","year":"2016","journal-title":"Journal of Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0805","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1076647","article-title":"Pregnancy-stimulated neurogenesis in the adult female forebrain mediated by prolactin","volume":"299","author":"Shingo","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0810","doi-asserted-by":"crossref","first-page":"E6544","DOI":"10.1073\/pnas.1518007112","article-title":"A basal stem cell signature identifies aggressive prostate cancer phenotypes","volume":"112","author":"Smith","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0815","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0820","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.1191","article-title":"Plasma prolactin and prostate cancer risk: A prospective study","volume":"92","author":"Stattin","year":"2001","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0825","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.humpath.2006.01.009","article-title":"STAT 5a expression in the breast is maintained in secretory carcinoma, in contrast to other histologic types","volume":"37","author":"Strauss","year":"2006","journal-title":"Human Pathology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0830","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1349-7006.2007.00685.x","article-title":"Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition","volume":"99","author":"Sultan","year":"2008","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0835","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/sj.onc.1208203","article-title":"Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells","volume":"24","author":"Sultan","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0840","first-page":"108","article-title":"The role of prolactin in bone metastasis and breast cancer cell-mediated osteoclast differentiation","author":"Sutherland","year":"2016","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0845","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0850","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.ajpath.2015.04.026","article-title":"Jak2-Stat5a\/b signaling induces epithelial-to-mesenchymal transition and stem-like cell properties in prostate cancer","volume":"185","author":"Talati","year":"2015","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0855","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fendo.2011.00029","article-title":"Investigation of prolactin receptor activation and blockade using time-resolved fluorescence resonance energy transfer","volume":"2","author":"Tallet","year":"2011","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0860","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10911-008-9066-8","article-title":"Rational design of competitive prolactin\/growth hormone receptor antagonists","volume":"13","author":"Tallet","year":"2008","journal-title":"Journal of Mammary Gland Biology and Neoplasia"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0865","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/0008-5472.CAN-07-2972","article-title":"Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells","volume":"68","author":"Tan","year":"2008","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0870","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1677\/ERC-08-0013","article-title":"Signal transducer and activator of transcription 5A\/B in prostate and breast cancers","volume":"15","author":"Tan","year":"2008","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0875","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0880","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/pros.22793","article-title":"Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting","volume":"74","author":"Thomas","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0885","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/pros.21446","article-title":"Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells","volume":"72","author":"Thomas","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0890","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-10-0850","article-title":"Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo","volume":"10","author":"Thomas","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0895","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13058-015-0563-6","article-title":"Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: A case-control study","volume":"17","author":"Tikk","year":"2015","journal-title":"Breast Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0900","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/annonc\/mdu150","article-title":"Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort","volume":"25","author":"Tikk","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0905","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005688","article-title":"A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors","volume":"5","author":"Toivanen","year":"2013","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0910","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10549-010-1025-6","article-title":"Amplification of the prolactin receptor gene in mammary lobular neoplasia","volume":"128","author":"Tran-Thanh","year":"2011","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0915","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1083\/jcb.200202067","article-title":"Proximal location of mouse prostate epithelial stem cells: A model of prostatic homeostasis","volume":"157","author":"Tsujimura","year":"2002","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0920","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/0008-5472.CAN-13-0665","article-title":"A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development","volume":"73","author":"Tworoger","year":"2013","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0925","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/bcr1829","article-title":"Mammographic density, breast cancer risk and risk prediction","volume":"9","author":"Vachon","year":"2007","journal-title":"Breast Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0930","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1210\/jc.2005-1899","article-title":"Association of prolactin and its receptor gene regions with familial breast cancer","volume":"91","author":"Vaclavicek","year":"2006","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0935","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jmb.2010.09.036","article-title":"Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone","volume":"404","author":"Van Agthoven","year":"2010","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0940","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/sj.onc.1203348","article-title":"Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth","volume":"19","author":"Vomachka","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0945","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0163-7258(98)00017-5","article-title":"Prolactin: The forgotten hormone of human breast cancer","volume":"79","author":"Vonderhaar","year":"1998","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0950","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10911-008-9062-z","article-title":"Jak2\/Stat5 signaling in mammogenesis, breast cancer initiation and progression","volume":"13","author":"Wagner","year":"2008","journal-title":"Journal of Mammary Gland Biology and Neoplasia"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2007.06.001","article-title":"S179D prolactin: Antagonistic agony!","volume":"276","author":"Walker","year":"2007","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0960","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature08361","article-title":"A luminal epithelial stem cell that is a cell of origin for prostate cancer","volume":"461","author":"Wang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0965","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ncb2697","article-title":"Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity","volume":"15","author":"Wang","year":"2013","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0970","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad3210","article-title":"ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling","volume":"9","author":"Wang","year":"2016","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0975","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.celrep.2014.08.002","article-title":"Luminal cells are favored as the cell of origin for prostate cancer","volume":"8","author":"Wang","year":"2014","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0980","doi-asserted-by":"crossref","first-page":"25998","DOI":"10.1038\/srep25998","article-title":"Plasma prolactin and breast cancer risk: A meta-analysis","volume":"6","author":"Wang","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0985","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0990","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/ph6080960","article-title":"The inhibition of stat5 by a peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells","volume":"6","author":"Weber","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb0995","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrclinonc.2009.166","article-title":"Histological and molecular types of breast cancer: Is there a unifying taxonomy?","volume":"6","author":"Weigelt","year":"2009","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb1000","first-page":"951","article-title":"Prolactin and murine mammary tumorigenesis: A review","volume":"37","author":"Welsch","year":"1977","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb1005","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.celrep.2014.03.009","article-title":"Antagonism of tumoral prolactin receptor promotes autophagy-related cell death","volume":"7","author":"Wen","year":"2014","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb1010","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1172\/JCI119820","article-title":"Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice","volume":"100","author":"Wennbo","year":"1997","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb1015","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1210\/endo.138.10.5461","article-title":"Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland","volume":"138","author":"Wennbo","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb1020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2015.06.010","article-title":"Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancer","volume":"366","author":"Yonezawa","year":"2015","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb1025","first-page":"173","article-title":"Residue 146 regulates prolactin receptor folding, basal activity and ligand-responsiveness: Potential implications in breast tumorigenesis","volume":"401C","author":"Zhang","year":"2014","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.05.009_bb1030","doi-asserted-by":"crossref","first-page":"11890","DOI":"10.1074\/jbc.M115.639096","article-title":"A residue quartet in the extracellular domain of the prolactin receptor selectively controls mitogen-activated protein kinase signaling","volume":"290","author":"Zhang","year":"2015","journal-title":"The Journal of Biological Chemistry"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817301286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817301286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T08:22:25Z","timestamp":1719217345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725817301286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":207,"alternative-id":["S0163725817301286"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.05.009","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}